Why the study?
A research gap exists in applying the prognostic value of the CHA2DS2-VASc scoring system to patients with stroke who do not have atrial fibrillation.
Does a higher CHA2DS2-VASc score predict major adverse cardiac events in patients with acute ischemic stroke without atrial fibrillation?
Population
993 patients with acute ischemic stroke without AF
Comparison
High-risk (score >2) vs moderate-risk (score 2) vs low-risk (score 0-1) CHA2DS2-VASc groups
Design
Observational cohort study
Follow-up
1 year
Authors
Loading...
Supports closer surveillance of high-score non-AF AIS patients; leaves open whether CHA2DS2-VASc should influence secondary prevention.
Does a higher CHA2DS2-VASc score predict major adverse cardiac events in patients with acute ischemic stroke without atrial fibrillation?
The CHA2DS2-VASc score effectively stratifies the 1-year risk of major adverse cardiac events in patients with acute ischemic stroke who do not have atrial fibrillation.
Song et al. (2025) studied this question.